Sullivan Christopher Ryan

Sullivan Christopher Ryan is listed in filings as Chief Financial Officer at Avalo Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 26, 2026, including sale activity. Recent filings connect the profile to Avalo Therapeutics, Inc. (AVTX). The current snapshot covers public activity from Aug 14, 2024 to May 26, 2026. Reported amounts are shown as $448.8K to $377.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.